Nevanac(nepafenac)
Ilevro, Nevanac (nepafenac) is a small molecule pharmaceutical. Nepafenac was first approved as Nevanac on 2005-08-19. It is used to treat eye pain in the USA. It has been approved in Europe to treat ophthalmologic surgical procedures and postoperative pain.
Download report
Favorite
Novartis Pharmaceuticals
Commercial
Trade Name
FDA
EMA
Ilevro, Nevanac
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| eye pain | HP_0200026 | D058447 | H57.1 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
53 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cataract | D002386 | EFO_0001059 | H26.9 | — | 3 | 8 | 6 | 2 | 19 |
| Macular edema | D008269 | — | 4 | 1 | 6 | 1 | 12 | ||
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | 1 | 2 | 4 |
| Inflammation | D007249 | — | 1 | 1 | 1 | 1 | 4 | ||
| Intraocular pressure | D007429 | — | — | — | 2 | — | 2 | ||
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | — | — | — | 1 | — | 1 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | 1 | — | 1 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | — | — | — | 1 | — | 1 |
| Pseudophakia | D019591 | — | — | — | 1 | — | 1 | ||
| Epiretinal membrane | D019773 | HP_0100014 | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic retinopathy | D003930 | EFO_0003770 | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Miosis | D015877 | HP_0000616 | H57.03 | — | 1 | — | — | — | 1 |
| Bacterial conjunctivitis | D003234 | EFO_1000829 | H10.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Angle-closure glaucoma | D015812 | — | — | — | — | 1 | 1 | ||
| Pain management | D059408 | — | — | — | — | 1 | 1 | ||
| Papilledema | D010211 | EFO_1001074 | H35.81 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NEPAFENAC |
| INN | nepafenac |
| Description | Nepafenac is a monocarboxylic acid amide that is amfenac in which the carboxylic acid group has been converted into the corresponding carboxamide. It is a prodrug for amfenac, used in eye drops to treat pain and inflammation following cataract surgery. It has a role as a prodrug, a cyclooxygenase 2 inhibitor, a cyclooxygenase 1 inhibitor, a non-steroidal anti-inflammatory drug and a non-narcotic analgesic. |
| Classification | Small molecule |
| Drug class | anti-inflammatory agents (acetic acid derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N |
Identifiers
| PDB | — |
| CAS-ID | 78281-72-8 |
| RxCUI | 298665 |
| ChEMBL ID | CHEMBL1021 |
| ChEBI ID | 75922 |
| PubChem CID | 151075 |
| DrugBank | DB06802 |
| UNII ID | 0J9L7J6V8C (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 813 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
774 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more